Search results
Results from the WOW.Com Content Network
More severe reactions are connected with allergic reactions to the medications and cardiovascular problems. Harvoni side effects are considered relatively mild compared to older interferon-based treatment. [citation needed] Ledipasvir/sofosbuvir could cause hepatitis B re-activation in people co-infected with hepatitis B and C viruses.
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [2] [5] [6] [7] It combines sofosbuvir and velpatasvir. [2] [5] [6] It is more than 90% effective for hepatitis C genotypes one through six. [2]
Drug holidays (or "structured treatment interruptions") are intentional discontinuations of antiretroviral drug treatment. As mentioned above, randomized controlled studies of structured treatment interruptions have shown higher rates of opportunistic infections, cancers, heart attacks and death in patients who took drug holidays.
It is on the World Health Organization's List of Essential Medicines. [9] In the United States, emtricitabine/tenofovir was under patent by Gilead until 2020, but is now available as a generic worldwide. [10] In 2020, it was the 278th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [11] [12]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Infusion-related reactions, skin reactions, hypomagnesaemia, hypocalcaemia, hypokalaemia, blood clots, interstitial lung disease and aseptic meningitis. Denosumab: SC: RANKL inhibitor. Osteoporosis, including drug- and cancer-related osteoporosis, giant cell tumour of bone and hypercalcaemia of malignancies
Wastewater data and reports from the Centers of Disease Control and Prevention have shown a significant spike in norovirus in the last few weeks, with rates far exceeding those of the past few years.
Between 1975 and 1999 only 13 of 1,300 new drugs were antiparasitics, which raised concerns that insufficient incentives existed to drive development of new treatments for diseases that disproportionately target low-income countries.